Product Candidates
|
VT-346 is a 43 kDa secreted glycoprotein that is a novel and potent inhibitor of human TNF-α. In pre-clinical testing, the compound has demonstrated an extremely high affinity for human TNF-α, in the order of 10-25 times that of some currently marketed anti-TNF therapies. The gene was isolated, cloned into a baculovirus expression system, and small amounts of the recombinant protein were purified and examined for binding activities using Biacore analysis. It was confirmed that the viral TNF-binding protein (TNF-bp) was able to bind human TNF-α with very high affinity (Table 1).
demonstrate potent binding to human TNF.
Preliminary in vivo data in a model of vascular inflammation also demonstrates potent drug effects at extremely low doses. |
|||||||||||||||||||








